Novartis Pharma Obtains Additional Approval for Its Proprietary Immunosuppressant Neoral.Tokyo, Japan, June 16, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Novartis Pharma has obtained additional approval for Neoral (cyclosporine cyclosporine /cy·clo·spor·ine/ (-spor´en) a cyclic peptide from an extract of soil fungi that selectively inhibits T cell function; used as an immunosuppressant to prevent rejection in organ transplant recipients and to treat severe ), its proprietary immunosuppressant immunosuppressant /im·mu·no·sup·pres·sant/ (-sah-pres´ant) an agent capable of suppressing immune responses. im·mu·no·sup·pres·sant n. An agent that suppresses the body's immune response. , from the Ministry of Health, Labor and Welfare. The agent is now available for the treatment of generalized myasthenia gravis myasthenia gravis (mīəsthē`nēə grä`vĭs), chronic disorder of the muscles characterized by weakness and a tendency to tire easily. . Initially released in May 2000, Neoral is used in the treatment of organ/bone-marrow transplant patients to prevent rejection, as well as for autoimmune diseases such as Behcet's syndrome and nephritic syndrome. The drug is currently available in 100 countries worldwide. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion